Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...

Medically reviewed by Jurairat J. Molina, MD Acute urticaria (hives) is a common skin condition that affects up to 20% of people at some point in their lives. It can transition into chronic urticaria ...

Some people have one flare-up and never get hives again. It’s also possible to have many flare-ups. If you continue to get hives daily or almost every day for six weeks or longer, you have chronic ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

This article will discuss the key differences between hives and eczema in their symptoms, causes, diagnosis, and treatment. Eczema, also called atopic dermatitis, is a chronic skin condition ...

If you have chronic hives, which means they linger for at least six weeks, you may be prescribed medications, including anti-inflammatory drugs, drugs that suppress the immune system, and drugs ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...

Novartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but the company says it has gone one better with new ...